TAS-102, a novel antitumor agent: A review of the mechanism of action

Cancer Treatment Reviews

Volumn 41, Issue 9, 2015, Pages 777-783

  Lenz, Heinz Josef ^a   Stintzing, Sebastian ^b   Loupakis, Fotios ^c  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c UNIVERSITY HOSPITAL OF PISA   (Italy)

Author keywords

5 Fluorouracil; Fluoropyrimidines; Mechanism of action; Metastatic colorectal cancer; TAS 102; Thymidylate synthase

Indexed keywords

CAPECITABINE; FLUOROURACIL; IRINOTECAN; OXALIPLATIN; THYMIDYLATE SYNTHASE; TIPIRACIL PLUS TRIFLURIDINE; TRIFLURIDINE; UFT; ANTINEOPLASTIC AGENT; DRUG COMBINATION; URACIL;

ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; BREAST CANCER; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; COLORECTAL CANCER; DIARRHEA; DNA DAMAGE; DNA SYNTHESIS; DRUG BIOAVAILABILITY; DRUG CYTOTOXICITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; GASTROINTESTINAL TOXICITY; GENE MUTATION; GROWTH INHIBITION; HUMAN; LEUKOPENIA; MAXIMUM PLASMA CONCENTRATION; METASTATIC COLORECTAL CANCER; NAUSEA; NEUTROPENIA; NONHUMAN; ONCOGENE K RAS; PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; STOMACH CANCER; STOMATITIS; TREATMENT DURATION; TUMOR GROWTH; VOMITING; ANALOGS AND DERIVATIVES; ANIMAL; CLINICAL TRIAL (TOPIC); DRUG COMBINATION; NEOPLASMS;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; DRUG COMBINATIONS; HUMANS; NEOPLASMS; TRIFLURIDINE; URACIL;

EID: 84944901084     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2015.06.001     Document Type: Review

References (80)

1. Heidelberger C. On the rational development of a new drug: the example of the fluorinated pyrimidines. Cancer Treat Rep 1981, 65(Suppl. 3):3-9.
2. Wilson P.M., Danenberg P.V., Johnston P.G., Lenz H.J., Ladner R.D. Standing the test of time: targeting thymidylate biosynthesis in cancer therapy. Nat Rev Clin Oncol 2014, 11(5):282-298.
3. Jackman A.L., Taylor G.A., Gibson W., Kimbell R., Brown M., Calvert A.H., et al. ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study. Cancer Res 1991, 51:5579-5586.
4. Shih C., Chen V.J., Gossett L.S., Gates S.B., MacKellar W.C., Habeck L.L., et al. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 1997, 57:1116-1123.
5. Longley D.B., Harkin D.P., Johnston P.G. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003, 3:330-338.
6. Temmink O.H., Emura T., de Bruin M., Fukushima M., Peters G.J. Therapeutic potential of the dual-targeted TAS-102 formulation in the treatment of gastrointestinal malignancies. Cancer Sci 2007, 98:779-789.
7. Mayer R.J., Van Cutsem E., Falcone A., Yoshino T., Garcia-Carbonero R., Mizunuma N., et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med 2015, 372:1909-1919.
8. Rahman L., Voeller D., Rahman M., Lipkowitz S., Allegra C., Barrett J.C., et al. Thymidylate synthase as an oncogene: a novel role for an essential DNA synthesis enzyme. Cancer Cell 2004, 5:341-351.
9. Hardy L.W., Finer-Moore J.S., Montfort W.R., Jones M.O., Santi D.V., Stroud R.M. Atomic structure of thymidylate synthase: target for rational drug design. Science 1987, 235:448-455.
10. Santi D.V., McHenry C.S. 5-Fluoro-2'-deoxyuridylate: covalent complex with thymidylate synthetase. Proc Natl Acad Sci U S A 1972, 69:1855-1857.
11. Santi D.V., McHenry C.S., Sommer H. Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxyuridylate. Biochemistry 1974, 13:471-481.
12. Goulian M., Bleile B.M., Dickey L.M., Grafstrom R.H., Ingraham H.A., Neynaber S.A., et al. Mechanism of thymineless death. Adv Exp Med Biol 1986, 195:89-95. Pt B.
13. Curtin N.J., Harris A.L., Aherne G.W. Mechanism of cell death following thymidylate synthase inhibition: 2'-deoxyuridine-5'-triphosphate accumulation, DNA damage, and growth inhibition following exposure to CB3717 and dipyridamole. Cancer Res 1991, 51:2346-2352.
14. Wyatt M.D., Wilson D.M. Participation of DNA repair in the response to 5-fluorouracil. Cell Mol Life Sci 2009, 66:788-799.
15. Grafstrom R.H., Tseng B.Y., Goulian M. The incorporation of uracil into animal cell DNA in vitro. Cell 1978, 15:131-140.
16. Webley S.D., Welsh S.J., Jackman A.L., Aherne G.W. The ability to accumulate deoxyuridine triphosphate and cellular response to thymidylate synthase (TS) inhibition. Br J Cancer 2001, 85:446-452.
17. Kufe D.W., Major P.P. 5-Fluorouracil incorporation into human breast carcinoma RNA correlates with cytotoxicity. J Biol Chem 1981, 256:9802-9805.
18. Glazer R.I., Lloyd L.S. Association of cell lethality with incorporation of 5-fluorouracil and 5-fluorouridine into nuclear RNA in human colon carcinoma cells in culture. Mol Pharmacol 1982, 21:468-473.
19. Aschele C., Sobrero A., Faderan M.A., Bertino J.R. Novel mechanism(s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules. Cancer Res 1992, 52:1855-1864.
20. Piedbois P., Rougier P., Buyse M., Pignon J., Ryan L., et al. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998, 16:301-308. Meta-analysis Group in Cancer.
21. Miwa M., Ura M., Nishida M., Sawada N., Ishikawa T., Mori K., et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998, 34:1274-1281.
22. Haller D.G., Cassidy J., Clarke S.J., Cunningham D., Van Cutsem E., Hoff P.M., et al. Potential regional differences for the tolerability profiles of fluoropyrimidines. J Clin Oncol 2008, 26:2118-2123.
23. Heggie G.D., Sommadossi J.P., Cross D.S., Huster W.J., Diasio R.B. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 1987, 47:2203-2206.
24. Lu Z.H., Zhang R., Diasio R.B. Purification and characterization of dihydropyrimidine dehydrogenase from human liver. J Biol Chem 1992, 267:17102-17109.
25. Saif M.W., Syrigos K., Mehra R., Mattison L.K., Diasio R.B. Dihydropyrimidine dehydrogenase deficiency (DPD) in GI malignancies: experience of 4-years. Pak J Med Sci 2007, 23:832-839.
26. 1-(2'-tetrahydrofuryl)-5-fluorouracil. Clin Cancer Res 1998, 4:2085-2088.
27. Shirasaka T., Nakano K., Takechi T., Satake H., Uchida J., Fujioka A., et al. Antitumor activity of 1M tegafur-0.4M 5-chloro-2,4-dihydroxypyridine-1M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res 1996, 56:2602-2606.
28. Chuah B., Goh B.C., Lee S.C., Soong R., Lau F., Mulay M., et al. Comparison of the pharmacokinetics and pharmacodynamics of S-1 between Caucasian and East Asian patients. Cancer Sci 2011, 102:478-483.
29. Hoff P.M., Saad E.D., Ajani J.A., Lassere Y., Wenske C., Medgyesy D., et al. Phase I study with pharmacokinetics of S-1 on an oral daily schedule for 28days in patients with solid tumors. Clin Cancer Res 2003, 9:134-142.
30. Heidelberger C., Chaudhuri N.K., Danneberg P., Mooren D., Griesbach L., Duschinsky R., et al. Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature 1957, 179:663-666.
31. Heidelberger C., Parsons D.G., Remy D.C. Syntheses of 5-trifluoromethyluracil and 5-trifluoromethyl-2'-deoxyuridine. J Med Chem 1964, 7:1-5.
32. Emura T., Suzuki N., Fujioka A., Ohshimo H., Fukushima M. Potentiation of the antitumor activity of alpha, alpha, alpha-trifluorothymidine by the co-administration of an inhibitor of thymidine phosphorylase at a suitable molar ratio in vivo. Int J Oncol 2005, 27:449-455.
33. Yoshino T., Mizunuma N., Yamazaki K., Nishina T., Komatsu Y., Baba H., et al. TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol 2012, 13:993-1001.
34. Dexter D.L., Wolberg W.H., Ansfield F.J., Helson L., Heidelberger C. The clinical pharmacology of 5-trifluoromethyl-2'-deoxyuridine. Cancer Res 1972, 32:247-253.
35. Fukushima M., Suzuki N., Emura T., Yano S., Kazuno H., Tada Y., et al. Structure and activity of specific inhibitors of thymidine phosphorylase to potentiate the function of antitumor 2'-deoxyribonucleosides. Biochem Pharmacol 2000, 59:1227-1236.
36. Salonga D., Danenberg K.D., Johnson M., Metzger R., Groshen S., Tsao-Wei D.D., et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 2000, 6:1322-1327.
37. Ansfield F.J., Ramirez G. Phase I and II studies of 2'-deoxy-5-(trifluoromethyl)-uridine (NSC-75520). Cancer Chemother Rep 1971, 55:205-208.
38. Tanaka N., Sakamoto K., Okabe H., Fujioka A., Yamamura K., Nakagawa F., et al. Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models. Oncol Rep 2014, 32:2319-2326.
39. Temmink O.H., Comijn E.M., Fukushima M., Peters G.J. Intracellular thymidylate synthase inhibition by trifluorothymidine in FM3A cells. Nucleosides Nucleotides Nucleic Acids 2004, 23:1491-1494.
40. Santi D.V., Sakai T.T. Thymidylate synthetase. Model studies of inhibition by 5-trifluoromethyl-2'-deoxyuridylic acid. Biochemistry 1971, 10:3598-3607.
41. Eckstein J.W., Foster P.G., Finer-Moore J., Wataya Y., Santi D.V. Mechanism-based inhibition of thymidylate synthase by 5-(trifluoromethyl)-2'-deoxyuridine 5'-monophosphate. Biochemistry 1994, 33:15086-15094.
42. Reyes P., Heidelberger C. Fluorinated pyrimidines. XXVI. Mammalian thymidylate synthetase: its mechanism of action and inhibition by fluorinated nucleotides. Mol Pharmacol 1965, 1:14-30.
43. Heidelberger C., Boohar J., Kampschroer B. Fluorinated pyrimidines. XXIV. In vivo metabolism of 5-trifluoromethyluracil-2-C-14 and 5-trifluoromethyl-2'-deoxyuridine-2-C-14. Cancer Res 1965, 25:377-381.
44. Fujiwara Y., Oki T., Heidelberger C. Fluorinated pyrimidines. XXXVII. Effects of 5-trifluoromethyl-2'-deoxyuridine on the synthesis of deoxyribonucleic acid of mammalian cells in culture. Mol Pharmacol 1970, 6:273-280.
45. Oguchi K., Sakamoto K., Kazuno H., Ueno H., Ishida K., Yokogawa T., et al. TAS-102 treatment results in high trifluridine incorporation into DNA with pyrimidine metabolic pathway markedly up-regulated in cancer. Eur J Cancer 2014, 50(Suppl. 6). [abstract 27].
46. Suzuki N., Emura T., Fukushima M. Mode of action of trifluorothymidine (TFT) against DNA replication and repair enzymes. Int J Oncol 2011, 39:263-270.
47. Matsuoka K., Iimori M., Niimi S., Tsukihara H., Watanabe S., Kiyonari S., et al. Trifluridine induces p53-dependent sustained G2 phase arrest with its massive misincorporation into DNA and few DNA strand breaks. Mol Cancer Ther 2015, 14:1004-1013.
48. Emura T., Nakagawa F., Fujioka A., Ohshimo H., Yokogawa T., Okabe H., et al. An optimal dosing schedule for a novel combination antimetabolite, TAS-102, based on its intracellular metabolism and its incorporation into DNA. Int J Mol Med 2004, 13:249-255.
49. Kavli B., Sundheim O., Akbari M., Otterlei M., Nilsen H., Skorpen F., et al. HUNG2 is the major repair enzyme for removal of uracil from U:A matches, U:G mismatches, and U in single-stranded DNA, with hSMUG1 as a broad specificity backup. J Biol Chem 2002, 277:39926-39936.
50. Grogan B.C., Parker J.B., Guminski A.F., Stivers J.T. Effect of the thymidylate synthase inhibitors on dUTP and TTP pool levels and the activities of DNA repair glycosylases on uracil and 5-fluorouracil in DNA. Biochemistry 2011, 50:618-627.
51. Pettersen H.S., Visnes T., Vågbø C.B., Svaasand E.K., Doseth B., Slupphaug G., et al. UNG-initiated base excision repair is the major repair route for 5-fluorouracil in DNA, but 5-fluorouracil cytotoxicity depends mainly on RNA incorporation. Nucleic Acids Res 2011, 39:8430-8444.
52. An Q., Robins P., Lindahl T., Barnes D.E. 5-Fluorouracil incorporated into DNA is excised by the Smug1 DNA glycosylase to reduce drug cytotoxicity. Cancer Res 2007, 67:940-945.
53. Kunz C., Focke F., Saito Y., Schuermann D., Lettieri T., Selfridge J., et al. Base excision by thymine DNA glycosylase mediates DNA-directed cytotoxicity of 5-fluorouracil. PLoS Biol 2009, 7:e91.
54. Turner D.P., Cortellino S., Schupp J.E., Caretti E., Loh T., Kinsella T.J., et al. The DNA N-glycosylase MED1 exhibits preference for halogenated pyrimidines and is involved in the cytotoxicity of 5-iododeoxyuridine. Cancer Res 2006, 66:7686-7693.
55. Petronzelli F., Riccio A., Markham G.D., Seeholzer S.H., Stoerker J., Genuardi M., et al. Biphasic kinetics of the human DNA repair protein MED1 (MBD4), a mismatch-specific DNA N-glycosylase. J Biol Chem 2000, 275:32422-32429.
56. Cortellino S., Turner D., Masciullo V., Schepis F., Albino D., Daniel R., et al. The base excision repair enzyme MED1 mediates DNA damage response to antitumor drugs and is associated with mismatch repair system integrity. Proc Natl Acad Sci U S A 2003, 100:15071-15076.
57. Moghaddam A., Zhang H.T., Fan T.P., Hu D.E., Lees V.C., Turley H., et al. Thymidine phosphorylase is angiogenic and promotes tumor growth. Proc Natl Acad Sci U S A 1995, 92:998-1002.
58. Hotchkiss K.A., Ashton A.W., Schwartz E.L. Thymidine phosphorylase and 2-deoxyribose stimulate human endothelial cell migration by specific activation of the integrins alpha 5 beta 1 and alpha V beta 3. J Biol Chem 2003, 278:19272-19279.
59. Matsushita S., Nitanda T., Furukawa T., Sumizawa T., Tani A., Nishimoto K., et al. The effect of a thymidine phosphorylase inhibitor on angiogenesis and apoptosis in tumors. Cancer Res 1999, 59:1911-1916.
60. Takao S., Akiyama S.I., Nakajo A., Yoh H., Kitazono M., Natsugoe S., et al. Suppression of metastasis by thymidine phosphorylase inhibitor. Cancer Res 2000, 60:5345-5348.
61. Murakami Y., Kazuno H., Emura T., Tsujimoto H., Suzuki N., Fukushima M. Different mechanisms of acquired resistance to fluorinated pyrimidines in human colorectal cancer cells. Int J Oncol 2000, 17:277-283.
62. Inaba M., Mitsuhashi J., Sawada H., Miike N., Naoe Y., Daimon A., et al. Reduced activity of anabolizing enzymes in 5-fluorouracil-resistant human stomach cancer cells. Jpn J Cancer Res 1996, 87:212-220.
63. Matsuoka K., Kobunai T., Takechi T. Efficacy of trifluridine for 5-fluorouracil-resistant human gastric cancer cell lines and their mechanisms. Cancer Res 2014, 74(Suppl. 19). [abstract 781].
64. Nakamura A., Nakajima G., Okuyama R., Kuramochi H., Kondoh Y., Kanemura T., et al. Enhancement of 5-fluorouracil-induced cytotoxicity by leucovorin in 5-fluorouracil-resistant gastric cancer cells with upregulated expression of thymidylate synthase. Gastric Cancer 2014, 17:188-195.
65. Sasaki K., Tsuno N.H., Sunami E., Tsurita G., Kawai K., Okaji Y., et al. Chloroquine potentiates the anti-cancer effect of 5-fluorouracil on colon cancer cells. BMC Cancer 2010, 10:370.
66. Sui X., Chen R., Wang Z., Huang Z., Kong N., Zhang M., et al. Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment. Cell Death Dis 2013, 4:e838.
67. Bijnsdorp I.V., Peters G.J., Temmink O.H., Fukushima M., Kruyt F.A. Differential activation of cell death and autophagy results in an increased cytotoxic potential for trifluorothymidine compared to 5-fluorouracil in colon cancer cells. Int J Cancer 2010, 126:2457-2468.
68. Temmink O.H., Hoebe E.K., Fukushima M., Peters G.J. Irinotecan-induced cytotoxicity to colon cancer cells in vitro is stimulated by pre-incubation with trifluorothymidine. Eur J Cancer 2007, 43:175-183.
69. Temmink O.H., Hoebe E.K., van der Born K., Ackland S.P., Fukushima M., Peters G.J. Mechanism of trifluorothymidine potentiation of oxaliplatin-induced cytotoxicity to colorectal cancer cells. Br J Cancer 2007, 96:231-240.
70. Ishida K., Sakamoto K., Tanaka N., Oguchi K., Yamamura K., Fujioka A., et al. Novel combination therapy, TAS-102 combined with the anti-EGFR antibody or the anti-VEGF antibody showed therapeutic benefit toward colorectal cancer xenografts. Eur J Cancer 2014, 50(Suppl. 6). [abstract 22].
71. Tsukihara H., Nakagawa F., Sakamoto K., Ishida K., Tanaka N., Okabe H., et al. Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, together with bevacizumab, cetuximab, or panitumumab on human colorectal cancer xenografts. Oncol Rep 2015, 33:2135-2142.
72. Nukatsuka M, Nakagawa F, Takechi T. Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, with oxaliplatin on human colorectal and gastric cancer xenografts. Anticancer Res (in press).
73. Nukatsuka M., Nakagawa F., Saito H., Sakata M., Uchida J., Takechi T. Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, with irinotecan hydrochloride on human colorectal and gastric cancer xenografts. Anticancer Res 2015, 35:1437-1445.
74. Hong D.S., Abbruzzese J.L., Bogaard K., Lassere Y., Fukushima M., Mita A., et al. Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors. Cancer 2006, 107:1383-1390.
75. Overman M.J., Kopetz S., Varadhachary G., Fukushima M., Kuwata K., Mita A., et al. Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid tumors. Cancer Invest 2008, 26:794-799.
76. Overman M.J., Varadhachary G., Kopetz S., Thomas M.B., Fukushima M., Kuwata K., et al. Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors. Invest New Drugs 2008, 26:445-454.
77. Green M.C., Pusztai L., Theriault L.R., Adinin R.B., Hofweber M., Fukushima M., et al. Phase I study to determine the safety of oral administration of TAS-102 on a twice daily (BID) schedule for five days a week (wk) followed by two days rest for two wks, every (Q) four wks in patients (pts) with metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2006, 24. [abstract 10576].
78. Doi T., Ohtsu A., Yoshino T., Boku N., Onozawa Y., Fukutomi A., et al. Phase I study of TAS-102 treatment in Japanese patients with advanced solid tumours. Br J Cancer 2012, 107:429-434.
79. Patel M.R., Bendell J.C., Mayer R.J., Benedetti F.M., Rosen L.S. A phase I dose-escalation study of TAS-102 in patients (pts) with refractory metastatic colorectal cancer (mCRC). J Clin Oncol 2012, 30(Suppl.). [abstract 3631].
80. Muro K., Doi T., Bando H., Yasui H., Nishina T., Yamaguchi K., et al. Multicenter phase 2 study of TAS-102 monotherapy in patients with pretreated advanced gastric cancer. Eur J Cancer 2013, 49(Suppl. 2). [abstract 2621].